Introduction
KSA. MEAD was prepared using previously described protocol with slight modification [17] . Briefly, the edible part of date fruit was manually separated, freeze dried and coarsely powdered using pestle and mortar. The powdered contents were then extracted in methanol (1:3 ratio, weight to volume) on a shaking incubator (Human Lab, Gyeonggi-Do, Korea) at 25°C for 48 h. The resultant extract was filtered using Whatman No. 1 filter paper and centrifuged at 4000 g for 15 min and vaporized under low pressure at 45°C using Rotavapor 1 R-300 (Buchi, Flawil Switzerland). The supernatant was separated and freeze dried using a lyophilizer (ilShin Biobase Europe, The Netherlands). The freeze dried powder was aliquoted and stored at -80°C until use in the experiments.
Cell culture
The human breast adenocarcinoma cell line (MCF7) was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Institutional ethical approval was obtained for use of cancer cells in this study. The MCF7 cells were maintained Dulbecco's minimal essential medium (DMEM), low glucose (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and 0.01 mg/ml bovine insulin and 1% penicillin-streptomycin, (Invitrogen, Carlsbad, CA) at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .
Cell imaging
MCF7 cells were cultured in 24-well tissue culture plates (Beckton, Dickinson, Franklin Lanes, NJ) at a seeding density of 2×10 4 cells/well. After overnight attachment, the cells were treated with different concentrations (5, 10, 15, 20 and 25 mg/ml) of MEAD and the untreated cells served as control (S1 Methods). The cells were cultured for up to 72 h under standard culture conditions of 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Changes in cell morphology were imaged using inverted phase contrast microscope (Nikon Instruments, Tokyo Japan).
Cell proliferation assay
The effects of MEAD on MCF7 proliferation/inhibition was analyzed using MTT reagent [18] . Briefly, 2×10 4 cells/well were seeded in 24-well plates and allowed to attach overnight. The cells were then treated with different concentrations (5, 10, 15, 20 and 25 mg/ml) of MEAD and incubated at 37°C in a humidified atmosphere with 5% CO 2 for up to 72 h. Following the treatment period, MTT reagent (5 mg/ml) in 100 μl of fresh culture medium was added to each well and incubated for 4 h. The formazan crystals formed with MTT treatment were solubilized with DMSO and the optical density was measured at 570 nm with a reference wavelength of 630 nm using a microplate ELISA reader (SpectraMax 1 i3x, Molecular Devices, Sunnyvale, CA). Percentage of inhibition was calculated as control-test/control Ã 100 [19] and IC50 was estimated (S2 Methods).
Cell cycle analysis
MCF7 cells were plated at a seeding density of 3×10 5 cells/T25 flask and allowed to attach overnight. The cells were treated with three different concentrations (15, 20 and 25 mg/ml) of MEAD. Untreated cells served as negative control and doxorubicin (DOX) 50 μM was used as a positive control. After 24 h of incubation, the cells were trypsinized and washed with Dulbecco's phosphate buffered saline (PBS) containing no calcium and magnesium. The pellet was resuspended into single cell suspension and fixed with chilled 70% ethanol and kept overnight at -20°C temperature. Before analysis, the cells were centrifuged at 300 g for 5 min and washed twice with PBS. Cells were resuspended in 400 μl staining solution containing 0.5 μg/ml RNase A and 50 μg/ml propidium iodide (PI). Following 15 min of incubation in the dark, the cells were analyzed using the FACS Aria III flow cytometer (BD Biosc iences, San Jose, CA). Caspase activation assay 
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Quantitative Real Time-PCR (qRT-PCR)
MCF7 cells were seeded at a density of 2×10 5 cells/T25 tissue culture flasks and allowed to attach overnight. They were then treated with 15 mg/ml and 20 mg/ml of MEAD and cultured for 48 h. The untreated cells served as a control. Total RNA was extracted from the experimental and control cells using Pure Link 1 RNA Mini Kit (Ambion™, ThermoFischer Scientific, Waltham, MA) which included DNase-I treatment protocol. RNA quantity and quality were measured using Nanodrop™ spectrophotometer (NanoDrop products, Wilmington, CA). Firststrand cDNA synthesis was performed using random hexamers (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems). Primer sequences (Table 1 ) used in the study were obtained from earlier published studies [20] . qRT-PCR analysis was performed using the ABI
Step One Plus Real-Time PCR System (Applied Biosystems, Foster City, CA) using SYBR green dye master mix and relative quantification was performed using the comparative 2 -ΔΔCt method.
Statistical analysis
The differences observed between the control and treated groups for cell proliferation, cell cycle, apoptosis, caspase activation and MMP were analyzed using either One-way ANOVA or unpaired Student t-test (two-tailed) using GraphPad Prism 6 (GraphPad Software, San Diego, USA). The results were expressed as the Mean ± SEM (standard error of mean) from three different replicates and a value of p<0.05 was considered statistically significant.
Results
MEAD induced changes in cell morphology
Phase contrast microscopy of untreated MCF7 cells demonstrated their characteristic epithelial nature and prolific growth as a monolayer. The cells appeared ovoid with central large nucleus with one or two nucleoli. In contrast, the MEAD treated cells showed mild to moderate decrease in cell numbers (S1 Fig) that were both time and dose dependent resulting in the presence of very few live cells (Fig 1) . Cell shrinkage was observed starting from 10 mg/ml of MEAD. Cytoplasmic condensation, membrane disruptions, detachment and cell death were most evident in MCF7 cells treated with 20 mg/ml and 25 mg/ml of MEAD (Fig 1) .
MEAD inhibited MCF7 proliferation
MTT assay demonstrated MCF7 growth inhibition following treatment with MEAD in a dose and time-dependent manner (Fig 2A-2C) . Moderate decrease in cell numbers by 41.85 ± 4.6 percent was observed following incubation with 15 mg/ml MEAD for 48 h (Fig 2B) compared to the control. There was a decrease in cell numbers at 20 mg/ml concentration at 48 h and 72 h that ranged from 78.20 ± 1.34 to 96 ± 2.03 percentages respectively (Fig 2C) . The cell proliferation showed a significant decrease (99.12 ± 0.08) in MCF7 cells treated with 25 mg/ml of MEAD at 72 h. The IC50 was determined to be 18.20 mg/ml (S2 and S3 Figs) for the 48 h duration. The decrease in proliferations were statistically significant (p<0.001). 
doi:10.1371/journal.pone.0158963.t001 
MEAD induced 'S' phase arrest in MCF7 cells
Cell cycle assay of MCF7 cells following treatment with different concentrations of MEAD (15, 20 and 25 mg/ml) showed altered cell cycle pattern compared to untreated controls ( Fig  3A) . There was a dose-dependent cell cycle arrest in the 'S' phase and a decrease in 'G1' phase of cell cycle in the treated group compared to the control (Fig 3B-3D ).
MEAD induced apoptosis in MCF7 cells
Annexin V-FITC and PI double staining of MCF7 cells treated with 15 mg/ml and 25 mg/ml concentrations of MEAD showed dose dependent increase in the number of apoptotic cells. The increases in total apoptotic cells were 21.45 ± 0.4% and 68.15 ± 1.55% for 15 mg/ml and 25 mg/ml of MEAD (S5 Fig) respectively compared to control 1% (Fig 4A-4C ). These increase in apoptosis was statistically significant compared to the control (Fig 4D) . 
MEAD increased TUNEL positive cells
Flow cytometric evaluation of DNA fragmentation in MCF7 cells treated with 15 mg/ml and 25 mg/ml of MEAD for 48 h showed dose dependent increase in the numbers of TUNEL positive cells compared to the untreated control (Fig 5A) . This increase in TUNEL positive cells were 3.0 ± 2.40% and 58.25 ± 0.65% for 15 mg/ml and 25 mg/ml of MEAD respectively (Fig 5B  and 5C ).
MEAD increased expression of apoptotic proteins
The expression levels of Bax, Bcl-2 and p53 were analyzed using flowcytometry (Fig 6) . A dose dependent increase in the expression of p53 and Bax was observed in treated MCF7 cells as compared to the untreated control. There were more than 4 fold and 10 fold increase in the expression of p53 upon treatment of cells with 15 and 20 mg/ml MEAD respectively, as compared to the control. Bcl-2 inhibitor ABT-737, used as a positive control showed 11 fold increase in the expression of p53 as compared to the control (S6 Fig). Bax expression demonstrated more than 7 fold and 10 fold increase upon treatment of cells with 15 and 20 mg/ml MEAD respectively, as compared to the control. ABT-737 showed 1.6 fold decrease in Bax as compared to control. The expression of Bcl-2 decreased from 88.1% in untreated cells to 71.1% and 64% (Fig 6B) upon treatment with 15 and 20 mg/ml MEAD respectively. Treatment with ABT-737 showed 6% reduction in the expression of Bcl-2.
MEAD increased Caspase 3 activity
Treatment of MCF7 cells with MEAD showed a dose dependent increase in active Caspase 3 expression by FACS analysis. There was an increase in active caspase 3 staining (Fig 7B and  7C ) by 32% and 37% following treatment with 15 mg/ml and 20 mg/ml MEAD respectively compared to the control (Fig 7A) . Treatment with ABT-737 (10 μM) also demonstrated an increase in active caspase 3 expression.
MEAD affects mitochondrial membrane potential in MCF7 cells
Treatment of MCF7 cells with 15 and 20 mg/ml MEAD showed a mild increase of green fluorescent JC-1 8.4% and 7% (Fig 8B and 8C) respectively, compared to the control (Fig 8A) . Treatment of cells with ABT-737 (10 μM), demonstrated 88% green fluorescent JC-1 staining, indicating a robust reduction of MMP (Fig 8D) .
MEAD up-regulated apoptotic gene expression
qRT-PCR analysis of the apoptotic related gene expression of MCF7 cells treated with 15 mg/ ml and 25 mg/ml of MEAD for 48 h demonstrated an increase in Bcl-2, p53, Fas and FasL compared to the control. The fold increases were 18.07 ± 0.40, 42.87 ± 0.15 and 30.23 ± 0.49 for p53, Fas and FasL respectively and these increases were statistically significant (Fig 9A) . The fold increases for Bax and Bcl-2 were 6.40 ± 0.03 and 3.20 ± 0.25 respectively (Fig 9A) . In addition, there was a dose-dependent increase in Bax/Bcl-2 ratio from 0.29 ± 0.12 to 2.44 ± 0.12 ( Fig 9B) .
Discussion
In this study, we have elucidated the anticancer effects of MEAD on MCF7 cells. MEAD inhibited the growth and proliferation of MCF7 cells. It also induced MCF7 cell death in a dose and time dependent manner. Natural products and their secondary metabolites have been demonstrated to induce apoptosis and/or modulate apoptotic pathways [20] . Many of the phytochemicals that exist in natural products/extracts such as flavonoids, aglycones, terepenoids and polyphenolic compounds are reported to have cancer inhibitory properties. Most importantly, in the last two decades some of them were subjected to clinical studies for various cancers including colon, liver, prostate, lung and breast cancer [21] . Cancer cells develop mechanism to regulate signaling pathways in order to escape host immune surveillance and avoid cell death, facilitating their prolonged survival [22] . The proliferative advantage conferred on these cells in turn promote their uncontrolled metastasis. Inhibition of their proliferation by induction of cell cycle arrest or apoptosis would be an advantage. Interestingly, in the present study, MEAD showed various morphological changes that were indicative of apoptosis. The cellular changes included membrane blebbing, cell contraction, cell fragmentation and loss of cell adherence leading on to cell death (Fig 1) . In addition, both annexin V-FITC co-staining with PI as well as the TUNEL assays demonstrated annexin V-FITC and TUNEL positive cells following treatment with MEAD. These results are in support of our morphological findings and further point towards apoptosis of MCF7 cells by MEAD. Externalization of phosphatidylserine (PS) associated with loss of cell membrane asymmetry and fragmentation of nuclear DNA are considered to be the hallmarks of cells in later stages of apoptosis [23] . Our findings are similar to an earlier study where pancreatic cancer cells treated with myricetin showed an increase in annexin-V and TUNEL positive cells [24] .
Mitochondria play a central role in both cell survival and cell death. Depolarization of mitochondrial membrane potential causes translocation of Bax from the cytosol to the outer mitochondrial membrane as well as the release of cytochrome c. These events then orchestrate apoptosome complex formation and activation of intrinsic apoptotic pathway [25] [26] . In the present study, the MCF7 cells treated with MEAD, demonstrated mild MMP changes compared to the control (Fig 8) indicating that the apoptotic events are mediated through the intrinsic pathway. However, significant caspase 3 activation was also noted in MCF7 cells treated with MEAD indicating that additional pathways of apoptosis are involved. Activation of the caspases including caspase 8 and caspase 3 are implicated in ligand mediated extrinsic pathway of apoptosis [27] . Quercetin, apigenin luteolin and myricetin are some of the common constituents of Ajwa date extract [15] . Interestingly, these compounds are reported to cause cancer cell inhibition [28] [29] [30] . Independent studies have demonstrated the anticancer effects of quercetin, where human breast cancer cells (MDA-MB-231 and MCF7) were inhibited in a dose and time dependent manner [31] . Quercetin also caused cell cycle arrest, increased proapoptotic Bax protein, reduced MMP and activated caspase 3, 8 and 9 leading to apoptosis [31, 32] .
Cell cycle regulation and cell death signaling pathways play a very important role in the developmental biology [32] . Dysregulation of cell signaling pathways leads to cancerous transformation and therefore serve as the potential targets for cancer therapeutics [32] . The cell cycle analysis in our study demonstrated 'S' phase arrest and decreased 'G1' phase following treatment with MEAD indicating that the extract and its components can bring about cell cycle arrest and inhibit the proliferation of cancer cells. MCF7 cell proliferation in vitro was inhibited in a dose and time dependent manner (Fig 2) . This was in line with an earlier report where the methanolic extract of date pollen was found to have anti-proliferative effects on MCF7, Caco-2 and Hela-1 cell lines [33] .
In line with our other results, the gene expression showed a significant increase in p53, Bax, Fas and FasL indicative of apoptotic cell death. p53 on stabilization and accumulation causes transcriptional regulation of different processes like cell cycle, apoptosis and DNA repair. Bax, PUMA and NOXA are up-regulated in apoptosis, while Bcl-2 family genes are down-regulated [34] . p53 up-regulate the transcription of Fas and enhances its processing and release through the Golgi apparatus [35, 36] . Probably, the increase in p53 led to the transcriptional activation of other dependent pro-apoptotic genes such as Fas, FasL, and Bax. Increased expression of Bax and p53 protein in our study further support that apoptotic cell death of MCF7 could be due to p53 dependent mechanism. In addition, there was a decrease in anti-apoptotic Bcl-2 and increase in the ratio of Bax/Bcl-2 transcription suggesting that MCF7 cell death following treatment with MEAD was activated by p53 mediated signaling leading to apoptosis. Quercetin, one of the metabolite of Ajwa date induces apoptosis by arresting cells in 'S' phase and 'G1' phase; expression of p53, P57 and Bax proteins; changes in mitochondrial membrane potential and activation of caspases in MCF7 cells [31] . This is in accordance with our results showing 'S' phase arrest and over expression of p53 and increased Bax/Bcl-2 ratio in MEAD treated MCF7 cells.
Plant extract have many different phytochemicals and metabolites, that may interact in a synergistic manner to exert their potential benefits to fight against the multifactorial and multistage carcinogenesis process [37] . Although it is important to purify the different components of the extract and identify their independent effects on both normal and cancer cell lines, at times the very process of purification may lead to the loss of these active compounds and hence their useful properties. Undue caution should therefore be exercised in isolation of individual components, as in some instances only the whole extract may actually be beneficial. This is emphasized by the fact that total extracts obtained from cranberry, pomegranate and Nigella sativa demonstrated much higher inhibitory effects in various cancers than their individual fractions [38] [39] [40] . Their beneficial effects were attributed to the synergistic effects of many individual components in the extract.
Conclusion
MEAD induces cell cycle arrest and causes cell death via apoptosis by activating both intrinsic and extrinsic pathways in MCF7 cells. Unlike conventional chemotherapeutics, MEAD is observed to exert only mild to moderate beneficial effects against MCF7 cells. Purification of MEAD and the identification of individual components that are responsible for anti-cancer properties will pave way for the development of novel anticancer therapeutics. In addition, the aglycone metabolites of Ajwa dates such as Luteolin, myricetin, apigenin, quercetin and petunidin have been reported to induce apoptosis in cancers [41] [42] [43] [44] . Given the folklore claims of cancer inhibitory properties of Ajwa date extract and our results on MCF7 cells, the date fruits could be added daily as a nutritional supplement for synergistic chemopreventive effects against breast cancer and other malignancies. 
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